Cancer Clinical Trials

When the way forward isn’t clear…

Maybe a clinical trial is right for you.

If you or a loved one has cancer and the current treatment option isn’t working, a clinical trial might be right for you. Clinical trials offer the latest therapy to improve on the standard of care and to test how new medical approaches work when other methods have failed. Clinical treatments have resulted in new treatments and prevention options for cancer care.

Participation in a cancer clinical trial also offers more interactive, precise and personalized care for you. Your treatment team is broader, coming from a range of disciplines. This allows more individualized attention to your care. A Phase I clinical trial can also allow you to stay closer to your home setting without having to travel to another destination.

If you are interested in learning more about a clinical trial, complete the form below or call (864) 920-2523. (This number is answered Monday through Friday, 8:30 a.m. to 5 p.m.  Please leave a voice message after business hours and your call will be returned within two business days.)

View below all of our active clinical trials.

Request Information on Clinical Trials

Someone will contact you within two business days.

How May We Help You?

Contact us: (864) 920-2523

Monday through Friday, 8:30 a.m. to 5 p.m.
or leave a message after business hours if you need active treatment for cancer. These trials do not pay you for participation.

Learn more about Clinical Trials

Learn more about clinical trials supported by National Cancer Institute (NCI) in this brief video.

Clinical Trials Available

Current Clinical Trials

Disease SiteStudyLocation
Disease Site: Lymphoma

USO 16065/TG Therapeutics UTX-TGR-205   View on ClinicalTrials.gov
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

OP Cancer Institute Research
864-241-6251
Disease Site: Cervical

RTOG 0724   View on ClinicalTrials.gov
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT with or without Adjuvant Chemotherapy in High-risk Patients with Early Stage Cervical Cancer Following Radical Hysterectomy

OP Cancer Institute Research
864-241-6251
Disease Site: Supportive Care

URCC 16070   View on ClinicalTrials.gov
Treatment of Refractory Nausea

OP Cancer Institute Research
864-241-6251
Disease Site: Amyloidosis

SWOG S1702   View on ClinicalTrials.gov
A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis;

OP Cancer Institute Research
864-241-6251
Disease Site: Lung: Non-Small Cell

Novartis CINC280A2201   View on ClinicalTrials.gov
A Phase II, Multicenter, Four-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-type (wt), Advanced Non-small cell lung cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease

OP Cancer Institute Research
864-241-6251
Disease Site: Bladder

ALLIANCE A031501   View on ClinicalTrials.gov
PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION

OP Cancer Institute Research
864-241-6251
Disease Site: Lymphoma

USO 16100/BMS CA209655   View on ClinicalTrials.gov
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

OP Cancer Institute Research
864-241-6251
Disease Site: Breast

NRG BR003   View on ClinicalTrials.gov
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

OP Cancer Institute Research
864-241-6251
Disease Site: Colon

ALLIANCE A021502/ATOMIC   View on ClinicalTrials.gov
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC)

OP Cancer Institute Research
864-241-6251
Disease Site: Renal

SWOG S1500   View on ClinicalTrials.gov
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

OP Cancer Institute Research
864-241-6251